Compare · AGL vs FMS
AGL vs FMS
Side-by-side comparison of agilon health inc. (AGL) and Fresenius Medical Care AG (FMS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AGL and FMS operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- FMS is the larger of the two at $19.85B, about 3.3x AGL ($6.03B).
- AGL has been more active in the news (7 items in the past 4 weeks vs 1 for FMS).
- AGL has more recent analyst coverage (25 ratings vs 21 for FMS).
- Company
- agilon health inc.
- Fresenius Medical Care AG
- Price
- $26.01-0.80%
- $22.76+0.02%
- Market cap
- $6.03B
- $19.85B
- 1M return
- +143.08%
- -
- 1Y return
- -72.94%
- -
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NYSE
- NYSE
- IPO
- 2021
- News (4w)
- 7
- 1
- Recent ratings
- 25
- 21
agilon health inc.
agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. The company was founded in 2016 and is based in Long Beach, California.
Fresenius Medical Care AG
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2020, it operated 4,092 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Latest AGL
- SEC Form DEFA14A filed by agilon health inc.
- SEC Form DEF 14A filed by agilon health inc.
- SEC Form 4 filed by Zamore Denise
- SEC Form 4 filed by Venkatachaliah Girish
- SEC Form 4 filed by Gertsch Timothy
- SEC Form 4 filed by Shaker Benjamin
- agilon health Sets Date to Report First Quarter 2026 Financial Results
- SEC Form 4 filed by Schwaneke Jeffrey A.
- SEC Form 4 filed by Shaker Benjamin
- SEC Form 4 filed by Gertsch Timothy
Latest FMS
- SEC Form 6-K filed by Fresenius Medical Care AG
- SEC Form 3 filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG
- SEC Form IRANNOTICE filed by Fresenius Medical Care AG
- SEC Form 20-F filed by Fresenius Medical Care AG
- Fresenius Medical Care delivers 27% earnings growth in 2025 and reaches upper end of its financial outlook; margin within 2025 mid-term target band
- SEC Form 6-K filed by Fresenius Medical Care AG
- Fresenius Medical downgraded by Goldman
- SEC Form 6-K filed by Fresenius Medical Care AG
- Fresenius Medical Care accelerates the second tranche of its EUR 1 billion share buyback program with around EUR 415 million repurchase planned